Markets:

Overview

News

Currencies

International

Treasuries

Arcturus Therapeutics Holdings Inc (NQ:ARCT)

6.740 -0.060 (-0.88%)

Streaming Delayed Price Updated: 10:47 AM EST, Nov 26, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Arcturus Therapeutics Holdings Inc

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

December 17, 2021

From Arcturus Therapeutics Holdings Inc.

Via Business Wire

58 Biggest Movers From Yesterday ↗

December 17, 2021

Gainers Adagio Therapeutics, Inc. (NASDAQ: ADGI) shares jumped 123.3% to settle at $14.18 on Thursday after traders circulated rumors of a reiterated Buy rating and $46 price...

Via Benzinga

Expert Ratings For Arcturus Therapeutics ↗

August 31, 2021

Within the last quarter, Arcturus Therapeutics (NASDAQ:ARCT) has observed ...

Via Benzinga

Analyst Ratings For Arcturus Therapeutics ↗

August 25, 2021

Analysts have provided the following ratings for Arcturus Therapeutics (NASDAQ:

Via Benzinga

Arcturus Shares Shoot Higher After Additional Data From COVID-19 Vaccine Programs ↗

December 16, 2021

Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) announced new data and updates from clinical development programs for ARCT-154 and ARCT-165, its self-amplifying...

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

December 16, 2021

Gainers Calliditas Therapeutics (NASDAQ:CALT...

Via Benzinga

31 Stocks Moving In Thursday's Mid-Day Session ↗

December 16, 2021

Gainers Calliditas Therapeutics AB (NASDAQ: CALT) shares climbed 28.7% to $24.13 after the company announced it was granted by the FDA accelerated approval of TARPEYO to reduce...

Via Benzinga

Arcturus Therapeutics Reports New Data and Provides Additional Updates from ARCT-154 and ARCT-165 Clinical Trials

December 16, 2021

From Arcturus Therapeutics Holdings Inc.

Via Business Wire

Arcturus Therapeutics Appoints Jing Marantz, M.D., Ph.D., M.B.A. to its Board of Directors

December 13, 2021

From Arcturus Therapeutics Holdings Inc.

Via Business Wire

Arcturus Therapeutics to Participate in Piper Sandler 33rd Annual Healthcare Conference

November 22, 2021

From Arcturus Therapeutics Holdings Inc.

Via Business Wire

Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

November 18, 2021

From Arcturus Therapeutics Holdings Inc.

Via Business Wire

Arcturus Therapeutics Announces Third Quarter 2021 Financial Update and Pipeline Progress

November 08, 2021

From Arcturus Therapeutics Holdings Inc.

Via Business Wire

Arcturus Therapeutics to Report Third Quarter 2021 Financial Results and Provide Corporate Update on November 8, 2021

October 25, 2021

From Arcturus Therapeutics Holdings Inc.

Via Business Wire

Arcturus Therapeutics Announces Leadership Appointments

October 21, 2021

From Arcturus Therapeutics Holdings Inc.

Via Business Wire

92 Biggest Movers From Friday ↗

November 08, 2021

Gainers Mainz Biomed B.V. (NASDAQ: MYNZ) shares jumped 99.8% to close at $9.99 on Friday. Mainz Biomed priced its initial public offering of 2 million ordinary shares at $5, the...

Via Benzinga

Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

October 20, 2021

From Arcturus Therapeutics Holdings Inc.

Via Business Wire

Arcturus Therapeutics Announces Approval from Vietnam Ministry of Health to Proceed into Phase 3b Study for ARCT-154, a Next Generation STARR™ mRNA Vaccine Targeting SARS-CoV-2 Delta Variant and Other Variants of Concern

October 12, 2021

From Arcturus Therapeutics Holdings Inc.

Via Business Wire

Merck Keeps M&A Mode On With Mirati, Biogen, mRNA Companies On Radar: FT ↗

October 06, 2021

Merck & Co Inc (NYSE: MRK) remains in a deal-hunting mode despite its recent $11.5 billion acquisition of Acceleron. Related: Merck Seals Acceleron Pharma Deal...

Via Benzinga

Arcturus Therapeutics Stock Sees Relative Strength Rating Rise To 83 ↗

September 29, 2021

Arcturus Therapeutics sees its Relative Strength Rating hit the 80-plus level.

Via Investor's Business Daily

Arcturus Therapeutics Announces Meeting with President of Vietnam and CEO of Vingroup to Discuss Expansion of COVID-19 Vaccine Collaboration

September 22, 2021

From Arcturus Therapeutics Holdings Inc.

Via Business Wire

Vietnam's Health Ministry Approves Phase 2, Phase 3 Cohorts Of Arcturus' COVID-19 Vaccine Trial ↗

September 22, 2021

Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) has completed dosing of 100 subjects for the Phase 1 portion of the ARCT-154 Phase 1/2/3 trial, which consisted...

Via Benzinga

The Daily Biotech Pulse: Pfizer-BioNTech US Vaccine Contract, Summit Slumps On Adverse Regulatory Feedback, Cerevel CFO Departs ↗

September 22, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 20) Acceleron Pharma Inc. (...

Via Benzinga

Arcturus Therapeutics Announces Approval from Vietnam Ministry of Health to Proceed into Phase 2 and Phase 3a for ARCT-154, Next Generation STARR™ mRNA Vaccine Targeting SARS-CoV-2 Delta Variant and Other Variants of Concern

September 22, 2021

From Arcturus Therapeutics Holdings Inc.

Via Business Wire

Arcturus Therapeutics Earnings Perspective: Return On Capital Employed ↗

September 15, 2021

According to Benzinga Pro data, during Q2, Arcturus Therapeutics (NASDAQ:ARCT) posted sales of $2.00 million. Earnings were up 6.84%, but Arcturus Therapeutics still reported an...

Via Benzinga

Arcturus Therapeutics to Participate in Citi's 16th Annual BioPharma Virtual Conference 2021

September 08, 2021

From Arcturus Therapeutics Holdings Inc.

Via Business Wire

Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences

September 07, 2021

From Arcturus Therapeutics Holdings Inc.

Via Business Wire

Mid-Day Market Update: ExOne Rises Following Acquisition News; LifeStance Health Shares Plummet ↗

August 12, 2021

Midway through trading Thursday, the Dow traded down 0.32% to 35,369.96 while the NASDAQ rose 0.01% to 14,766.11. The S&P also fell, dropping 0.10% to 4,443.23. The U.S. has...

Via Benzinga

Topics Stocks

Benzinga's Top Ratings Upgrades, Downgrades For August 12, 2021 ↗

August 12, 2021

Upgrades According to Northland Capital Markets, the prior rating for Points International Ltd

Via Benzinga

Arcturus Stock, A Covid Play, Flashes Vital Signs ↗

August 11, 2021

A Relative Strength Rating upgrade for Alcobra shows improving technical performance.

Via Investor's Business Daily

Benzinga's Top Ratings Upgrades, Downgrades For August 11, 2021 ↗

August 11, 2021

Upgrades According to Barclays, the prior rating for Albertsons Companies Inc (NYSE:

Via Benzinga

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.